DK2262520T3 - COMPOSITIONS FOR PREVENTION AND TREATMENT OF Kidney Injury - Google Patents

Info

Publication number

DK2262520T3

DK2262520T3 DK09713874.7T DK09713874T DK2262520T3 DK 2262520 T3 DK2262520 T3 DK 2262520T3 DK 09713874 T DK09713874 T DK 09713874T DK 2262520 T3 DK2262520 T3 DK 2262520T3

Authority

DK

Denmark

Prior art keywords

renal

subject

dye

group

contrast

Prior art date

2008-02-26

Links

• Espacenet
• Global Dossier
• Discuss

• 238000011282 treatment Methods 0.000 title claims description 74
• 239000000203 mixture Substances 0.000 title claims description 38
• 206010061481 Renal injury Diseases 0.000 title claims description 13
• 208000037806 kidney injury Diseases 0.000 title claims description 6
• 230000002265 prevention Effects 0.000 title description 17
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 160
• 208000009304 Acute Kidney Injury Diseases 0.000 claims description 98
• 210000003734 kidney Anatomy 0.000 claims description 71
• 239000003795 chemical substances by application Substances 0.000 claims description 40
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 32
• 239000000994 contrast dye Substances 0.000 claims description 32
• 229960004316 cisplatin Drugs 0.000 claims description 31
• 230000003589 nefrotoxic effect Effects 0.000 claims description 22
• 231100000381 nephrotoxic Toxicity 0.000 claims description 21
• CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 18
• VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 claims description 18
• 150000001875 compounds Chemical class 0.000 claims description 16
• XQZXYNRDCRIARQ-LURJTMIESA-N iopamidol Chemical compound C[C@H](O)C(=O)NC1=C(I)C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C1I XQZXYNRDCRIARQ-LURJTMIESA-N 0.000 claims description 16
• -1 ioglicate Chemical compound 0.000 claims description 15
• 229960004647 iopamidol Drugs 0.000 claims description 13
• KCWZGJVSDFYRIX-YFKPBYRVSA-N N(gamma)-nitro-L-arginine methyl ester Chemical compound COC(=O)[C@@H](N)CCCN=C(N)N[N+]([O-])=O KCWZGJVSDFYRIX-YFKPBYRVSA-N 0.000 claims description 11
• 208000033626 Renal failure acute Diseases 0.000 claims description 11
• 201000011040 acute kidney failure Diseases 0.000 claims description 11
• YVPYQUNUQOZFHG-UHFFFAOYSA-N amidotrizoic acid Chemical compound CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I YVPYQUNUQOZFHG-UHFFFAOYSA-N 0.000 claims description 11
• 230000001684 chronic effect Effects 0.000 claims description 11
• 229960005423 diatrizoate Drugs 0.000 claims description 11
• 229960000905 indomethacin Drugs 0.000 claims description 9
• 239000008194 pharmaceutical composition Substances 0.000 claims description 9
• 229930183010 Amphotericin Natural products 0.000 claims description 7
• QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 claims description 7
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 7
• 108010036949 Cyclosporine Proteins 0.000 claims description 7
• CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 7
• 229930182566 Gentamicin Natural products 0.000 claims description 7
• 229940009444 amphotericin Drugs 0.000 claims description 7
• APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims description 7
• CZTQZXZIADLWOZ-CRAIPNDOSA-N cefaloridine Chemical compound O=C([C@@H](NC(=O)CC=1SC=CC=1)[C@H]1SC2)N1C(C(=O)[O-])=C2C[N+]1=CC=CC=C1 CZTQZXZIADLWOZ-CRAIPNDOSA-N 0.000 claims description 7
• 229960003866 cefaloridine Drugs 0.000 claims description 7
• 229960001265 ciclosporin Drugs 0.000 claims description 7
• 229930182912 cyclosporin Natural products 0.000 claims description 7
• 229960002518 gentamicin Drugs 0.000 claims description 7
• NTHXOOBQLCIOLC-UHFFFAOYSA-N iohexol Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NTHXOOBQLCIOLC-UHFFFAOYSA-N 0.000 claims description 7
• 108010048898 phenylalanyl-arginyl-phenylalanyllysinamide Proteins 0.000 claims description 7
• ZMJOVJSTYLQINE-UHFFFAOYSA-N Dichloroacetylene Chemical group ClC#CCl ZMJOVJSTYLQINE-UHFFFAOYSA-N 0.000 claims description 6
• UXIGWFXRQKWHHA-UHFFFAOYSA-N Iotalamic acid Chemical compound CNC(=O)C1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I UXIGWFXRQKWHHA-UHFFFAOYSA-N 0.000 claims description 6
• 229960001025 iohexol Drugs 0.000 claims description 6
• 229940029378 iothalamate Drugs 0.000 claims description 6
• 229960000554 metrizamide Drugs 0.000 claims description 6
• GGGDNPWHMNJRFN-UHFFFAOYSA-N metrizoic acid Chemical compound CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I GGGDNPWHMNJRFN-UHFFFAOYSA-N 0.000 claims description 6
• GNOGSFBXBWBTIG-UHFFFAOYSA-N Acetrizoic acid Chemical compound CC(=O)NC1=C(I)C=C(I)C(C(O)=O)=C1I GNOGSFBXBWBTIG-UHFFFAOYSA-N 0.000 claims description 5
• BAQCROVBDNBEEB-UBYUBLNFSA-N Metrizamide Chemical compound CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C(=O)N[C@@H]2[C@H]([C@H](O)[C@@H](CO)OC2O)O)=C1I BAQCROVBDNBEEB-UBYUBLNFSA-N 0.000 claims description 5
• XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical group ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 claims description 5
• VVDGWALACJEJKG-UHFFFAOYSA-N iodamide Chemical compound CC(=O)NCC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I VVDGWALACJEJKG-UHFFFAOYSA-N 0.000 claims description 5
• 229960004901 iodamide Drugs 0.000 claims description 4
• 229960004712 metrizoic acid Drugs 0.000 claims description 4
• UBOXGVDOUJQMTN-UHFFFAOYSA-N trichloroethylene Natural products ClCC(Cl)Cl UBOXGVDOUJQMTN-UHFFFAOYSA-N 0.000 claims description 4
• 229950005499 carbon tetrachloride Drugs 0.000 claims 2
• 229960002415 trichloroethylene Drugs 0.000 claims 1
• DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 132
• 102000004196 processed proteins & peptides Human genes 0.000 description 114
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 90
• 239000000975 dye Substances 0.000 description 90
• 241000700159 Rattus Species 0.000 description 84
• 239000002872 contrast media Substances 0.000 description 73
• 229940109239 creatinine Drugs 0.000 description 66
• 238000000034 method Methods 0.000 description 58
• 210000002966 serum Anatomy 0.000 description 54
• 230000000694 effects Effects 0.000 description 47
• 210000004027 cell Anatomy 0.000 description 44
• 208000028867 ischemia Diseases 0.000 description 42
• 108090000623 proteins and genes Proteins 0.000 description 42
• 102000004169 proteins and genes Human genes 0.000 description 41
• 230000003907 kidney function Effects 0.000 description 40
• 238000010171 animal model Methods 0.000 description 37
• 235000011187 glycerol Nutrition 0.000 description 36
• 229960005150 glycerol Drugs 0.000 description 36
• 241001465754 Metazoa Species 0.000 description 34
• 208000004608 Ureteral Obstruction Diseases 0.000 description 34
• 230000002485 urinary effect Effects 0.000 description 34
• 230000006378 damage Effects 0.000 description 32
• 235000002639 sodium chloride Nutrition 0.000 description 32
• 208000007788 Acute Liver Failure Diseases 0.000 description 31
• 206010000804 Acute hepatic failure Diseases 0.000 description 31
• 231100000836 acute liver failure Toxicity 0.000 description 31
• 239000003814 drug Substances 0.000 description 30
• 238000010186 staining Methods 0.000 description 30
• 229940039231 contrast media Drugs 0.000 description 29
• 229940079593 drug Drugs 0.000 description 27
• 210000002700 urine Anatomy 0.000 description 26
• 239000003981 vehicle Substances 0.000 description 24
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 23
• 239000011780 sodium chloride Substances 0.000 description 22
• 150000001413 amino acids Chemical class 0.000 description 21
• 238000002474 experimental method Methods 0.000 description 21
• 230000001965 increasing effect Effects 0.000 description 21
• 210000000110 microvilli Anatomy 0.000 description 21
• 208000027418 Wounds and injury Diseases 0.000 description 20
• 230000006907 apoptotic process Effects 0.000 description 20
• 230000007423 decrease Effects 0.000 description 20
• 208000014674 injury Diseases 0.000 description 20
• 208000017169 kidney disease Diseases 0.000 description 20
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 19
• 206010016654 Fibrosis Diseases 0.000 description 18
• 230000004761 fibrosis Effects 0.000 description 18
• 230000010410 reperfusion Effects 0.000 description 18
• 210000005239 tubule Anatomy 0.000 description 18
• 238000002347 injection Methods 0.000 description 17
• 229940090044 injection Drugs 0.000 description 17
• 239000007924 injection Substances 0.000 description 17
• 230000003247 decreasing effect Effects 0.000 description 16
• 230000002829 reductive effect Effects 0.000 description 16
• 210000004369 blood Anatomy 0.000 description 15
• 239000008280 blood Substances 0.000 description 15
• 230000017074 necrotic cell death Effects 0.000 description 15
• 206010028851 Necrosis Diseases 0.000 description 14
• 201000010099 disease Diseases 0.000 description 14
• 230000037396 body weight Effects 0.000 description 13
• 206010012601 diabetes mellitus Diseases 0.000 description 13
• 210000002540 macrophage Anatomy 0.000 description 13
• 238000001000 micrograph Methods 0.000 description 13
• 239000000126 substance Substances 0.000 description 13
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 12
• 108010018924 Heme Oxygenase-1 Proteins 0.000 description 12
• 102000002737 Heme Oxygenase-1 Human genes 0.000 description 12
• 206010039020 Rhabdomyolysis Diseases 0.000 description 12
• 230000001640 apoptogenic effect Effects 0.000 description 12
• 210000003470 mitochondria Anatomy 0.000 description 12
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 10
• 210000002950 fibroblast Anatomy 0.000 description 10
• 230000008595 infiltration Effects 0.000 description 10
• 238000001764 infiltration Methods 0.000 description 10
• 230000009467 reduction Effects 0.000 description 10
• 230000008085 renal dysfunction Effects 0.000 description 10
• 150000003839 salts Chemical class 0.000 description 10
• 230000001988 toxicity Effects 0.000 description 10
• 231100000419 toxicity Toxicity 0.000 description 10
• 230000002238 attenuated effect Effects 0.000 description 9
• 230000008859 change Effects 0.000 description 9
• 239000011630 iodine Substances 0.000 description 9
• 229910052740 iodine Inorganic materials 0.000 description 9
• 231100000417 nephrotoxicity Toxicity 0.000 description 9
• 239000003642 reactive oxygen metabolite Substances 0.000 description 9
• 239000000243 solution Substances 0.000 description 9
• 208000024891 symptom Diseases 0.000 description 9
• 241000124008 Mammalia Species 0.000 description 8
• 206010029155 Nephropathy toxic Diseases 0.000 description 8
• 238000000692 Student's t-test Methods 0.000 description 8
• 230000001976 improved effect Effects 0.000 description 8
• 239000000178 monomer Substances 0.000 description 8
• 230000007694 nephrotoxicity Effects 0.000 description 8
• 230000004792 oxidative damage Effects 0.000 description 8
• 239000012188 paraffin wax Substances 0.000 description 8
• 210000000512 proximal kidney tubule Anatomy 0.000 description 8
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
• 102000004190 Enzymes Human genes 0.000 description 7
• 108090000790 Enzymes Proteins 0.000 description 7
• 208000020832 chronic kidney disease Diseases 0.000 description 7
• 230000008021 deposition Effects 0.000 description 7
• 238000000151 deposition Methods 0.000 description 7
• 229940088598 enzyme Drugs 0.000 description 7
• 238000009472 formulation Methods 0.000 description 7
• 230000006870 function Effects 0.000 description 7
• 230000024924 glomerular filtration Effects 0.000 description 7
• 230000035755 proliferation Effects 0.000 description 7
• 210000005234 proximal tubule cell Anatomy 0.000 description 7
• 210000005084 renal tissue Anatomy 0.000 description 7
• 238000001356 surgical procedure Methods 0.000 description 7
• RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 6
• 108010088751 Albumins Proteins 0.000 description 6
• 102000009027 Albumins Human genes 0.000 description 6
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
• BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 6
• 102000008186 Collagen Human genes 0.000 description 6
• 108010035532 Collagen Proteins 0.000 description 6
• 108010061642 Cystatin C Proteins 0.000 description 6
• 102000012192 Cystatin C Human genes 0.000 description 6
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
• TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 6
• 239000006172 buffering agent Substances 0.000 description 6
• 230000000747 cardiac effect Effects 0.000 description 6
• 229920001436 collagen Polymers 0.000 description 6
• 239000000539 dimer Substances 0.000 description 6
• 239000008103 glucose Substances 0.000 description 6
• 230000004054 inflammatory process Effects 0.000 description 6
• 230000003908 liver function Effects 0.000 description 6
• 238000000386 microscopy Methods 0.000 description 6
• 210000000056 organ Anatomy 0.000 description 6
• 230000035699 permeability Effects 0.000 description 6
• 229920001184 polypeptide Polymers 0.000 description 6
• 230000000069 prophylactic effect Effects 0.000 description 6
• 201000002793 renal fibrosis Diseases 0.000 description 6
• ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 6
• 230000001225 therapeutic effect Effects 0.000 description 6
• 210000001519 tissue Anatomy 0.000 description 6
• 230000002407 ATP formation Effects 0.000 description 5
• 208000003918 Acute Kidney Tubular Necrosis Diseases 0.000 description 5
• 241000282412 Homo Species 0.000 description 5
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 5
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
• 206010061218 Inflammation Diseases 0.000 description 5
• 208000001647 Renal Insufficiency Diseases 0.000 description 5
• 206010062237 Renal impairment Diseases 0.000 description 5
• 206010038540 Renal tubular necrosis Diseases 0.000 description 5
• 230000001154 acute effect Effects 0.000 description 5
• 208000012998 acute renal failure Diseases 0.000 description 5
• 208000022831 chronic renal failure syndrome Diseases 0.000 description 5
• 230000006735 deficit Effects 0.000 description 5
• 208000035475 disorder Diseases 0.000 description 5
• 230000000302 ischemic effect Effects 0.000 description 5
• 201000006370 kidney failure Diseases 0.000 description 5
• 210000004379 membrane Anatomy 0.000 description 5
• 239000012528 membrane Substances 0.000 description 5
• 231100000637 nephrotoxin Toxicity 0.000 description 5
• 230000007935 neutral effect Effects 0.000 description 5
• 230000005298 paramagnetic effect Effects 0.000 description 5
• 231100000857 poor renal function Toxicity 0.000 description 5
• 201000001474 proteinuria Diseases 0.000 description 5
• 238000011084 recovery Methods 0.000 description 5
• 229910052708 sodium Inorganic materials 0.000 description 5
• 239000003381 stabilizer Substances 0.000 description 5
• 230000009885 systemic effect Effects 0.000 description 5
• 208000037816 tissue injury Diseases 0.000 description 5
• 231100000331 toxic Toxicity 0.000 description 5
• 230000002588 toxic effect Effects 0.000 description 5
• 238000002054 transplantation Methods 0.000 description 5
• 210000004926 tubular epithelial cell Anatomy 0.000 description 5
• 210000003462 vein Anatomy 0.000 description 5
• 238000009010 Bradford assay Methods 0.000 description 4
• 206010028980 Neoplasm Diseases 0.000 description 4
• 230000002159 abnormal effect Effects 0.000 description 4
• 239000000427 antigen Substances 0.000 description 4
• 102000036639 antigens Human genes 0.000 description 4
• 108091007433 antigens Proteins 0.000 description 4
• 238000004166 bioassay Methods 0.000 description 4
• 230000015572 biosynthetic process Effects 0.000 description 4
• 230000036770 blood supply Effects 0.000 description 4
• 210000000170 cell membrane Anatomy 0.000 description 4
• 230000018044 dehydration Effects 0.000 description 4
• 238000006297 dehydration reaction Methods 0.000 description 4
• 210000002919 epithelial cell Anatomy 0.000 description 4
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
• 230000003993 interaction Effects 0.000 description 4
• 210000004185 liver Anatomy 0.000 description 4
• 238000002595 magnetic resonance imaging Methods 0.000 description 4
• 238000004519 manufacturing process Methods 0.000 description 4
• 230000002438 mitochondrial effect Effects 0.000 description 4
• 230000000737 periodic effect Effects 0.000 description 4
• 239000012071 phase Substances 0.000 description 4
• 239000011734 sodium Substances 0.000 description 4
• 229960001052 streptozocin Drugs 0.000 description 4
• 230000008961 swelling Effects 0.000 description 4
• 238000012360 testing method Methods 0.000 description 4
• 206010001580 Albuminuria Diseases 0.000 description 3
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
• 229910052688 Gadolinium Inorganic materials 0.000 description 3
• 206010021143 Hypoxia Diseases 0.000 description 3
• AMDBBAQNWSUWGN-UHFFFAOYSA-N Ioversol Chemical compound OCCN(C(=O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I AMDBBAQNWSUWGN-UHFFFAOYSA-N 0.000 description 3
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 3
• MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 3
• 206010053159 Organ failure Diseases 0.000 description 3
• ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 3
• 102000003929 Transaminases Human genes 0.000 description 3
• 108090000340 Transaminases Proteins 0.000 description 3
• PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 3
• 238000010521 absorption reaction Methods 0.000 description 3
• 150000001298 alcohols Chemical class 0.000 description 3
• 229910021529 ammonia Inorganic materials 0.000 description 3
• 239000003963 antioxidant agent Substances 0.000 description 3
• 230000003078 antioxidant effect Effects 0.000 description 3
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
• 230000030833 cell death Effects 0.000 description 3
• 230000001413 cellular effect Effects 0.000 description 3
• OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 230000001419 dependent effect Effects 0.000 description 3
• 238000010790 dilution Methods 0.000 description 3
• 239000012895 dilution Substances 0.000 description 3
• 238000011156 evaluation Methods 0.000 description 3
• UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 3
• 230000001434 glomerular Effects 0.000 description 3
• 210000000585 glomerular basement membrane Anatomy 0.000 description 3
• 238000003306 harvesting Methods 0.000 description 3
• 230000002440 hepatic effect Effects 0.000 description 3
• 231100000753 hepatic injury Toxicity 0.000 description 3
• 235000009200 high fat diet Nutrition 0.000 description 3
• 238000003364 immunohistochemistry Methods 0.000 description 3
• 231100000268 induced nephrotoxicity Toxicity 0.000 description 3
• 230000028709 inflammatory response Effects 0.000 description 3
• 238000010255 intramuscular injection Methods 0.000 description 3
• 238000001990 intravenous administration Methods 0.000 description 3
• 229960004359 iodixanol Drugs 0.000 description 3
• NBQNWMBBSKPBAY-UHFFFAOYSA-N iodixanol Chemical compound IC=1C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(=O)C)CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NBQNWMBBSKPBAY-UHFFFAOYSA-N 0.000 description 3
• LAYLQVBQIBQVLL-UHFFFAOYSA-N iofendylate Chemical compound CCOC(=O)CCCCCCCCC(C)C1=CC=C(I)C=C1 LAYLQVBQIBQVLL-UHFFFAOYSA-N 0.000 description 3
• IUNJANQVIJDFTQ-UHFFFAOYSA-N iopentol Chemical compound COCC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I IUNJANQVIJDFTQ-UHFFFAOYSA-N 0.000 description 3
• DGAIEPBNLOQYER-UHFFFAOYSA-N iopromide Chemical compound COCC(=O)NC1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)N(C)CC(O)CO)=C1I DGAIEPBNLOQYER-UHFFFAOYSA-N 0.000 description 3
• 239000000463 material Substances 0.000 description 3
• 230000007246 mechanism Effects 0.000 description 3
• 230000001404 mediated effect Effects 0.000 description 3
• 229960003194 meglumine Drugs 0.000 description 3
• MIKKOBKEXMRYFQ-WZTVWXICSA-N meglumine amidotrizoate Chemical compound C[NH2+]C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I MIKKOBKEXMRYFQ-WZTVWXICSA-N 0.000 description 3
• 230000002503 metabolic effect Effects 0.000 description 3
• 229910021645 metal ion Inorganic materials 0.000 description 3
• MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 3
• 230000004065 mitochondrial dysfunction Effects 0.000 description 3
• 230000004048 modification Effects 0.000 description 3
• 238000012986 modification Methods 0.000 description 3
• 238000010369 molecular cloning Methods 0.000 description 3
• 239000003921 oil Substances 0.000 description 3
• 239000001301 oxygen Substances 0.000 description 3
• 229910052760 oxygen Inorganic materials 0.000 description 3
• 230000036284 oxygen consumption Effects 0.000 description 3
• 229960005489 paracetamol Drugs 0.000 description 3
• 239000002245 particle Substances 0.000 description 3
• 238000005192 partition Methods 0.000 description 3
• 239000000546 pharmaceutical excipient Substances 0.000 description 3
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
• 230000008569 process Effects 0.000 description 3
• 230000001681 protective effect Effects 0.000 description 3
• 239000007845 reactive nitrogen species Substances 0.000 description 3
• 238000003757 reverse transcription PCR Methods 0.000 description 3
• 230000002441 reversible effect Effects 0.000 description 3
• 239000007790 solid phase Substances 0.000 description 3
• 238000012453 sprague-dawley rat model Methods 0.000 description 3
• 238000007920 subcutaneous administration Methods 0.000 description 3
• 239000004094 surface-active agent Substances 0.000 description 3
• 238000003786 synthesis reaction Methods 0.000 description 3
• 229940124597 therapeutic agent Drugs 0.000 description 3
• 230000032258 transport Effects 0.000 description 3
• 230000010024 tubular injury Effects 0.000 description 3
• 208000037978 tubular injury Diseases 0.000 description 3
• 210000005233 tubule cell Anatomy 0.000 description 3
• 239000013598 vector Substances 0.000 description 3
• SFVLTCAESLKEHH-WKAQUBQDSA-N (2s)-6-amino-2-[[(2s)-2-[[(2r)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]amino]-n-[(2s)-1-amino-1-oxo-3-phenylpropan-2-yl]hexanamide Chemical compound CC1=CC(O)=CC(C)=C1C[C@H](NC(=O)[C@H](N)CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N)=O)CC1=CC=CC=C1 SFVLTCAESLKEHH-WKAQUBQDSA-N 0.000 description 2
• HUHDYASLFWQVOL-WZTVWXICSA-N 3-[[2-[[3-[acetyl(methyl)amino]-2,4,6-triiodo-5-(methylcarbamoyl)benzoyl]amino]acetyl]amino]-5-(2-hydroxyethylcarbamoyl)-2,4,6-triiodobenzoic acid;(2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC(=O)C1=C(I)C(N(C)C(C)=O)=C(I)C(C(=O)NCC(=O)NC=2C(=C(C(=O)NCCO)C(I)=C(C(O)=O)C=2I)I)=C1I HUHDYASLFWQVOL-WZTVWXICSA-N 0.000 description 2
• RYSMHWILUNYBFW-UHFFFAOYSA-N 4-amino-2-[6-(dimethylamino)purin-9-yl]-5-(hydroxymethyl)oxolan-3-ol Chemical compound C1=NC=2C(N(C)C)=NC=NC=2N1C1OC(CO)C(N)C1O RYSMHWILUNYBFW-UHFFFAOYSA-N 0.000 description 2
• 101710103970 ADP,ATP carrier protein Proteins 0.000 description 2
• 101710133192 ADP,ATP carrier protein, mitochondrial Proteins 0.000 description 2
• 208000010444 Acidosis Diseases 0.000 description 2
• 206010002091 Anaesthesia Diseases 0.000 description 2
• 244000105975 Antidesma platyphyllum Species 0.000 description 2
• 201000003126 Anuria Diseases 0.000 description 2
• 206010056375 Bile duct obstruction Diseases 0.000 description 2
• 206010005003 Bladder cancer Diseases 0.000 description 2
• 102000019034 Chemokines Human genes 0.000 description 2
• 108010012236 Chemokines Proteins 0.000 description 2
• 206010008635 Cholestasis Diseases 0.000 description 2
• 229930105110 Cyclosporin A Natural products 0.000 description 2
• 102100030497 Cytochrome c Human genes 0.000 description 2
• 108010075031 Cytochromes c Proteins 0.000 description 2
• 102000004127 Cytokines Human genes 0.000 description 2
• 108090000695 Cytokines Proteins 0.000 description 2
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
• 108020004414 DNA Proteins 0.000 description 2
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
• 108010067770 Endopeptidase K Proteins 0.000 description 2
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
• 102000016359 Fibronectins Human genes 0.000 description 2
• 108010067306 Fibronectins Proteins 0.000 description 2
• WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
• 102100028006 Heme oxygenase 1 Human genes 0.000 description 2
• 206010019851 Hepatotoxicity Diseases 0.000 description 2
• 101001079623 Homo sapiens Heme oxygenase 1 Proteins 0.000 description 2
• 208000002682 Hyperkalemia Diseases 0.000 description 2
• VLHUSFYMPUDOEL-WZTVWXICSA-N Iothalamate meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC(=O)C1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I VLHUSFYMPUDOEL-WZTVWXICSA-N 0.000 description 2
• XUHXFSYUBXNTHU-UHFFFAOYSA-N Iotrolan Chemical compound IC=1C(C(=O)NC(CO)C(O)CO)=C(I)C(C(=O)NC(CO)C(O)CO)=C(I)C=1N(C)C(=O)CC(=O)N(C)C1=C(I)C(C(=O)NC(CO)C(O)CO)=C(I)C(C(=O)NC(CO)C(O)CO)=C1I XUHXFSYUBXNTHU-UHFFFAOYSA-N 0.000 description 2
• UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
• YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
• 208000000913 Kidney Calculi Diseases 0.000 description 2
• LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical group CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
• 229930195725 Mannitol Natural products 0.000 description 2
• 206010027417 Metabolic acidosis Diseases 0.000 description 2
• 206010027525 Microalbuminuria Diseases 0.000 description 2
• 208000004221 Multiple Trauma Diseases 0.000 description 2
• 206010029148 Nephrolithiasis Diseases 0.000 description 2
• MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
• 208000008589 Obesity Diseases 0.000 description 2
• 206010030302 Oliguria Diseases 0.000 description 2
• 108091005804 Peptidases Proteins 0.000 description 2
• 102000035195 Peptidases Human genes 0.000 description 2
• 102000003992 Peroxidases Human genes 0.000 description 2
• 229920001213 Polysorbate 20 Polymers 0.000 description 2
• ROSXARVHJNYYDO-UHFFFAOYSA-N Propyliodone Chemical compound CCCOC(=O)CN1C=C(I)C(=O)C(I)=C1 ROSXARVHJNYYDO-UHFFFAOYSA-N 0.000 description 2
• 206010060862 Prostate cancer Diseases 0.000 description 2
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
• LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
• 108091036333 Rapid DNA Proteins 0.000 description 2
• 101001079613 Rattus norvegicus Heme oxygenase 1 Proteins 0.000 description 2
• 206010063897 Renal ischaemia Diseases 0.000 description 2
• 206010040047 Sepsis Diseases 0.000 description 2
• 238000012288 TUNEL assay Methods 0.000 description 2
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
• 206010047139 Vasoconstriction Diseases 0.000 description 2
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
• 241000700605 Viruses Species 0.000 description 2
• 238000009825 accumulation Methods 0.000 description 2
• 239000000654 additive Substances 0.000 description 2
• 230000002411 adverse Effects 0.000 description 2
• 230000001668 ameliorated effect Effects 0.000 description 2
• 230000037005 anaesthesia Effects 0.000 description 2
• 238000002583 angiography Methods 0.000 description 2
• 210000004102 animal cell Anatomy 0.000 description 2
• 150000001450 anions Chemical class 0.000 description 2
• 238000013459 approach Methods 0.000 description 2
• 239000007864 aqueous solution Substances 0.000 description 2
• 108010033284 arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide Proteins 0.000 description 2
• 230000001174 ascending effect Effects 0.000 description 2
• 238000003556 assay Methods 0.000 description 2
• 230000008499 blood brain barrier function Effects 0.000 description 2
• 230000017531 blood circulation Effects 0.000 description 2
• 230000036772 blood pressure Effects 0.000 description 2
• 210000001218 blood-brain barrier Anatomy 0.000 description 2
• 210000001124 body fluid Anatomy 0.000 description 2
• 239000010839 body fluid Substances 0.000 description 2
• 210000004556 brain Anatomy 0.000 description 2
• 201000011510 cancer Diseases 0.000 description 2
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
• 239000000969 carrier Substances 0.000 description 2
• 150000001768 cations Chemical class 0.000 description 2
• 238000004113 cell culture Methods 0.000 description 2
• 239000003153 chemical reaction reagent Substances 0.000 description 2
• 229960004926 chlorobutanol Drugs 0.000 description 2
• MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
• 238000010367 cloning Methods 0.000 description 2
• ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
• 230000034994 death Effects 0.000 description 2
• 230000007850 degeneration Effects 0.000 description 2
• 238000001514 detection method Methods 0.000 description 2
• 230000006866 deterioration Effects 0.000 description 2
• ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 2
• 239000002934 diuretic Substances 0.000 description 2
• 230000004064 dysfunction Effects 0.000 description 2
• 230000007705 epithelial mesenchymal transition Effects 0.000 description 2
• 230000029142 excretion Effects 0.000 description 2
• 210000002744 extracellular matrix Anatomy 0.000 description 2
• 210000001105 femoral artery Anatomy 0.000 description 2
• 238000001914 filtration Methods 0.000 description 2
• 239000012530 fluid Substances 0.000 description 2
• 238000013467 fragmentation Methods 0.000 description 2
• 238000006062 fragmentation reaction Methods 0.000 description 2
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
• 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 2
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
• 239000010931 gold Substances 0.000 description 2
• 229910052737 gold Inorganic materials 0.000 description 2
• 235000009424 haa Nutrition 0.000 description 2
• 210000002216 heart Anatomy 0.000 description 2
• 208000006750 hematuria Diseases 0.000 description 2
• 231100000304 hepatotoxicity Toxicity 0.000 description 2
• 230000007686 hepatotoxicity Effects 0.000 description 2
• 230000002209 hydrophobic effect Effects 0.000 description 2
• TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 2
• QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 2
• 230000007954 hypoxia Effects 0.000 description 2
• 239000012216 imaging agent Substances 0.000 description 2
• 210000001822 immobilized cell Anatomy 0.000 description 2
• 230000001771 impaired effect Effects 0.000 description 2
• 230000003834 intracellular effect Effects 0.000 description 2
• 150000008040 ionic compounds Chemical class 0.000 description 2
• 229960000824 iopentol Drugs 0.000 description 2
• 229960002603 iopromide Drugs 0.000 description 2
• 229960003182 iotrolan Drugs 0.000 description 2
• 229960004537 ioversol Drugs 0.000 description 2
• 229960003299 ketamine Drugs 0.000 description 2
• 238000011862 kidney biopsy Methods 0.000 description 2
• JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
• 210000000265 leukocyte Anatomy 0.000 description 2
• 230000000670 limiting effect Effects 0.000 description 2
• 229960001078 lithium Drugs 0.000 description 2
• 229910052744 lithium Inorganic materials 0.000 description 2
• 210000005229 liver cell Anatomy 0.000 description 2
• 229910052749 magnesium Inorganic materials 0.000 description 2
• 238000007726 management method Methods 0.000 description 2
• 239000000594 mannitol Substances 0.000 description 2
• 235000010355 mannitol Nutrition 0.000 description 2
• 229960001855 mannitol Drugs 0.000 description 2
• 239000011159 matrix material Substances 0.000 description 2
• 238000005259 measurement Methods 0.000 description 2
• 229910052751 metal Inorganic materials 0.000 description 2
• 239000002184 metal Substances 0.000 description 2
• 235000013336 milk Nutrition 0.000 description 2
• 239000008267 milk Substances 0.000 description 2
• 210000004080 milk Anatomy 0.000 description 2
• 230000005787 mitochondrial ATP synthesis coupled electron transport Effects 0.000 description 2
• 230000006540 mitochondrial respiration Effects 0.000 description 2
• 210000000651 myofibroblast Anatomy 0.000 description 2
• 239000012246 nephrotoxicant Substances 0.000 description 2
• 231100001115 nephrotoxicant Toxicity 0.000 description 2
• 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 2
• 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 2
• 239000003690 nonionic contrast media Substances 0.000 description 2
• 239000002736 nonionic surfactant Substances 0.000 description 2
• 108020004707 nucleic acids Proteins 0.000 description 2
• 102000039446 nucleic acids Human genes 0.000 description 2
• 150000007523 nucleic acids Chemical class 0.000 description 2
• 235000020824 obesity Nutrition 0.000 description 2
• 235000019198 oils Nutrition 0.000 description 2
• 210000004789 organ system Anatomy 0.000 description 2
• 150000002894 organic compounds Chemical class 0.000 description 2
• 238000012261 overproduction Methods 0.000 description 2
• 239000007800 oxidant agent Substances 0.000 description 2
• 230000003647 oxidation Effects 0.000 description 2
• 238000007254 oxidation reaction Methods 0.000 description 2
• 230000001590 oxidative effect Effects 0.000 description 2
• 230000010627 oxidative phosphorylation Effects 0.000 description 2
• 230000036542 oxidative stress Effects 0.000 description 2
• 230000001575 pathological effect Effects 0.000 description 2
• 238000010647 peptide synthesis reaction Methods 0.000 description 2
• 108040007629 peroxidase activity proteins Proteins 0.000 description 2
• 230000002085 persistent effect Effects 0.000 description 2
• 230000035479 physiological effects, processes and functions Effects 0.000 description 2
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
• 239000010491 poppyseed oil Substances 0.000 description 2
• 238000012545 processing Methods 0.000 description 2
• 230000000750 progressive effect Effects 0.000 description 2
• 229960003927 propyliodone Drugs 0.000 description 2
• 230000035939 shock Effects 0.000 description 2
• XZNXVSDNACTASG-RZNNTOFGSA-M sodium;3,5-diacetamido-2,4,6-triiodobenzoate;3,5-diacetamido-2,4,6-triiodobenzoic acid;(2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol Chemical compound [Na+].CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I XZNXVSDNACTASG-RZNNTOFGSA-M 0.000 description 2
• WCIMWHNSWLLELS-UHFFFAOYSA-M sodium;3-acetamido-2,4,6-triiodo-5-(methylcarbamoyl)benzoate Chemical compound [Na+].CNC(=O)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I WCIMWHNSWLLELS-UHFFFAOYSA-M 0.000 description 2
• 230000035882 stress Effects 0.000 description 2
• 239000000758 substrate Substances 0.000 description 2
• 239000006228 supernatant Substances 0.000 description 2
• 230000004083 survival effect Effects 0.000 description 2
• 238000013268 sustained release Methods 0.000 description 2
• 239000012730 sustained-release form Substances 0.000 description 2
• 239000008399 tap water Substances 0.000 description 2
• 235000020679 tap water Nutrition 0.000 description 2
• 229940126585 therapeutic drug Drugs 0.000 description 2
• 238000013518 transcription Methods 0.000 description 2
• 230000035897 transcription Effects 0.000 description 2
• 238000012546 transfer Methods 0.000 description 2
• 238000013519 translation Methods 0.000 description 2
• LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
• 238000002604 ultrasonography Methods 0.000 description 2
• 210000000626 ureter Anatomy 0.000 description 2
• 201000005112 urinary bladder cancer Diseases 0.000 description 2
• 230000025033 vasoconstriction Effects 0.000 description 2
• BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 2
• 229960001600 xylazine Drugs 0.000 description 2
• 239000008096 xylene Substances 0.000 description 2
• LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
• UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
• SBVRILUQXIOGSI-WZTVWXICSA-N 3-acetamido-2,4,6-triiodo-5-[[2-(methylamino)-2-oxoethyl]carbamoyl]benzoic acid;(2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC(=O)CNC(=O)C1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I SBVRILUQXIOGSI-WZTVWXICSA-N 0.000 description 1
• BAQCROVBDNBEEB-KSDLJXBFSA-N 3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodo-n-[(2s,3r,4r,5s,6r)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]benzamide Chemical compound CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C(=O)N[C@@H]2[C@H]([C@H](O)[C@@H](CO)O[C@@H]2O)O)=C1I BAQCROVBDNBEEB-KSDLJXBFSA-N 0.000 description 1
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
• OXEUETBFKVCRNP-UHFFFAOYSA-N 9-ethyl-3-carbazolamine Chemical compound NC1=CC=C2N(CC)C3=CC=CC=C3C2=C1 OXEUETBFKVCRNP-UHFFFAOYSA-N 0.000 description 1
• 239000005541 ACE inhibitor Substances 0.000 description 1
• 108091006112 ATPases Proteins 0.000 description 1
• 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
• ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 1
• 206010001605 Alcohol poisoning Diseases 0.000 description 1
• 206010002198 Anaphylactic reaction Diseases 0.000 description 1
• 108010089941 Apoptosomes Proteins 0.000 description 1
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
• 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
• 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
• 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
• 238000009020 BCA Protein Assay Kit Methods 0.000 description 1
• 241001354791 Baliga Species 0.000 description 1
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
• 208000014644 Brain disease Diseases 0.000 description 1
• 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
• 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
• 102000000905 Cadherin Human genes 0.000 description 1
• 108050007957 Cadherin Proteins 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 206010048610 Cardiotoxicity Diseases 0.000 description 1
• 229930186147 Cephalosporin Natural products 0.000 description 1
• VWFCHDSQECPREK-LURJTMIESA-N Cidofovir Chemical compound NC=1C=CN(C[C@@H](CO)OCP(O)(O)=O)C(=O)N=1 VWFCHDSQECPREK-LURJTMIESA-N 0.000 description 1
• 235000001258 Cinchona calisaya Nutrition 0.000 description 1
• 108050006400 Cyclin Proteins 0.000 description 1
• 102000000634 Cytochrome c oxidase subunit IV Human genes 0.000 description 1
• 108090000365 Cytochrome-c oxidases Proteins 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• 208000003870 Drug Overdose Diseases 0.000 description 1
• 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 238000012286 ELISA Assay Methods 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 108010024636 Glutathione Proteins 0.000 description 1
• 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
• 108010015899 Glycopeptides Proteins 0.000 description 1
• 102000002068 Glycopeptides Human genes 0.000 description 1
• 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
• 208000010496 Heart Arrest Diseases 0.000 description 1
• 208000032843 Hemorrhage Diseases 0.000 description 1
• 208000032456 Hemorrhagic Shock Diseases 0.000 description 1
• 206010019663 Hepatic failure Diseases 0.000 description 1
• 206010019799 Hepatitis viral Diseases 0.000 description 1
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
• PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
• 206010021137 Hypovolaemia Diseases 0.000 description 1
• 102000014150 Interferons Human genes 0.000 description 1
• 108010050904 Interferons Proteins 0.000 description 1
• 102000000588 Interleukin-2 Human genes 0.000 description 1
• 108010002350 Interleukin-2 Proteins 0.000 description 1
• 206010065973 Iron Overload Diseases 0.000 description 1
• UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical group OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical group CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
• QEFRNWWLZKMPFJ-ZXPFJRLXSA-N L-methionine (R)-S-oxide Chemical group C[S@@](=O)CC[C@H]([NH3+])C([O-])=O QEFRNWWLZKMPFJ-ZXPFJRLXSA-N 0.000 description 1
• QEFRNWWLZKMPFJ-UHFFFAOYSA-N L-methionine sulphoxide Chemical group CS(=O)CCC(N)C(O)=O QEFRNWWLZKMPFJ-UHFFFAOYSA-N 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 206010067125 Liver injury Diseases 0.000 description 1
• 239000002616 MRI contrast agent Substances 0.000 description 1
• 208000026680 Metabolic Brain disease Diseases 0.000 description 1
• 102000005741 Metalloproteases Human genes 0.000 description 1
• 108010006035 Metalloproteases Proteins 0.000 description 1
• 229930192392 Mitomycin Natural products 0.000 description 1
• 208000034486 Multi-organ failure Diseases 0.000 description 1
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
• 208000003510 Nephrogenic Fibrosing Dermopathy Diseases 0.000 description 1
• 206010067467 Nephrogenic systemic fibrosis Diseases 0.000 description 1
• 239000000020 Nitrocellulose Substances 0.000 description 1
• 108091005461 Nucleic proteins Proteins 0.000 description 1
• CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
• 206010061876 Obstruction Diseases 0.000 description 1
• 206010030113 Oedema Diseases 0.000 description 1
• 108091034117 Oligonucleotide Proteins 0.000 description 1
• 206010033296 Overdoses Diseases 0.000 description 1
• 238000009004 PCR Kit Methods 0.000 description 1
• 239000002033 PVDF binder Substances 0.000 description 1
• 206010033645 Pancreatitis Diseases 0.000 description 1
• 229930182555 Penicillin Natural products 0.000 description 1
• 208000018262 Peripheral vascular disease Diseases 0.000 description 1
• 206010057249 Phagocytosis Diseases 0.000 description 1
• RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 208000035965 Postoperative Complications Diseases 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 102000009339 Proliferating Cell Nuclear Antigen Human genes 0.000 description 1
• 101000916679 Rattus norvegicus Cystatin-C Proteins 0.000 description 1
• 108020004511 Recombinant DNA Proteins 0.000 description 1
• 208000027032 Renal vascular disease Diseases 0.000 description 1
• 206010049771 Shock haemorrhagic Diseases 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• 208000006011 Stroke Diseases 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
• 108700012920 TNF Proteins 0.000 description 1
• QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
• 208000007536 Thrombosis Diseases 0.000 description 1
• 206010070863 Toxicity to various agents Diseases 0.000 description 1
• 206010052779 Transplant rejections Diseases 0.000 description 1
• FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 1
• 108010059993 Vancomycin Proteins 0.000 description 1
• RRDRHWJDBOGQHN-JWCTVYNTSA-N [2-[(2s,5r,8s,11s,14r,17s,22s)-17-[(1r)-1-hydroxyethyl]-22-[[(2s)-2-[[(2s,3r)-3-hydroxy-2-[[(2s)-2-[6-methyloctanoyl(sulfomethyl)amino]-4-(sulfomethylamino)butanoyl]amino]butyl]amino]-4-(sulfomethylamino)butanoyl]amino]-5,8-bis(2-methylpropyl)-3,6,9,12,15 Chemical compound CCC(C)CCCCC(=O)N(CS(O)(=O)=O)[C@@H](CCNCS(O)(=O)=O)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCNCS(O)(=O)=O)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](CCNCS(O)(=O)=O)NC(=O)[C@H](CCNCS(O)(=O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCNCS(O)(=O)=O)NC1=O RRDRHWJDBOGQHN-JWCTVYNTSA-N 0.000 description 1
• 208000002223 abdominal aortic aneurysm Diseases 0.000 description 1
• 230000003187 abdominal effect Effects 0.000 description 1
• 238000002835 absorbance Methods 0.000 description 1
• 229960005216 acetrizoic acid Drugs 0.000 description 1
• 229960004150 aciclovir Drugs 0.000 description 1
• 239000002253 acid Substances 0.000 description 1
• 230000004913 activation Effects 0.000 description 1
• 239000008186 active pharmaceutical agent Substances 0.000 description 1
• 230000000996 additive effect Effects 0.000 description 1
• 239000000048 adrenergic agonist Substances 0.000 description 1
• 208000019269 advanced heart failure Diseases 0.000 description 1
• 238000000246 agarose gel electrophoresis Methods 0.000 description 1
• 230000032683 aging Effects 0.000 description 1
• 229960004821 amikacin Drugs 0.000 description 1
• LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 229940126575 aminoglycoside Drugs 0.000 description 1
• 229940124326 anaesthetic agent Drugs 0.000 description 1
• 238000004458 analytical method Methods 0.000 description 1
• 230000036783 anaphylactic response Effects 0.000 description 1
• 208000003455 anaphylaxis Diseases 0.000 description 1
• 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
• 238000000137 annealing Methods 0.000 description 1
• 230000003092 anti-cytokine Effects 0.000 description 1
• 230000000798 anti-retroviral effect Effects 0.000 description 1
• 239000002220 antihypertensive agent Substances 0.000 description 1
• 229940127088 antihypertensive drug Drugs 0.000 description 1
• 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
• 229940124522 antiretrovirals Drugs 0.000 description 1
• 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
• 210000000709 aorta Anatomy 0.000 description 1
• 208000007474 aortic aneurysm Diseases 0.000 description 1
• 238000003782 apoptosis assay Methods 0.000 description 1
• 230000005775 apoptotic pathway Effects 0.000 description 1
• 239000007900 aqueous suspension Substances 0.000 description 1
• 229910052788 barium Inorganic materials 0.000 description 1
• DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
• 229960000686 benzalkonium chloride Drugs 0.000 description 1
• 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
• CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 238000005415 bioluminescence Methods 0.000 description 1
• 230000029918 bioluminescence Effects 0.000 description 1
• 239000000090 biomarker Substances 0.000 description 1
• 230000000903 blocking effect Effects 0.000 description 1
• 229940098773 bovine serum albumin Drugs 0.000 description 1
• 230000036471 bradycardia Effects 0.000 description 1
• 208000006218 bradycardia Diseases 0.000 description 1
• 239000008366 buffered solution Substances 0.000 description 1
• 229940046731 calcineurin inhibitors Drugs 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
• 235000013539 calcium stearate Nutrition 0.000 description 1
• 239000008116 calcium stearate Substances 0.000 description 1
• 239000004202 carbamide Substances 0.000 description 1
• 229910052799 carbon Inorganic materials 0.000 description 1
• UHBYWPGGCSDKFX-UHFFFAOYSA-N carboxyglutamic acid Chemical compound OC(=O)C(N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-UHFFFAOYSA-N 0.000 description 1
• 238000012754 cardiac puncture Methods 0.000 description 1
• 231100000259 cardiotoxicity Toxicity 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 229960004261 cefotaxime Drugs 0.000 description 1
• AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 description 1
• 230000005779 cell damage Effects 0.000 description 1
• 208000037887 cell injury Diseases 0.000 description 1
• 230000005754 cellular signaling Effects 0.000 description 1
• 238000005119 centrifugation Methods 0.000 description 1
• 229940124587 cephalosporin Drugs 0.000 description 1
• 150000001780 cephalosporins Chemical class 0.000 description 1
• 239000013522 chelant Substances 0.000 description 1
• 238000007385 chemical modification Methods 0.000 description 1
• 239000012707 chemical precursor Substances 0.000 description 1
• 229940112822 chewing gum Drugs 0.000 description 1
• 235000015218 chewing gum Nutrition 0.000 description 1
• HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Substances ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 1
• 229960000724 cidofovir Drugs 0.000 description 1
• LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
• 229960003405 ciprofloxacin Drugs 0.000 description 1
• 229940105442 cisplatin injection Drugs 0.000 description 1
• 239000007979 citrate buffer Substances 0.000 description 1
• 239000004927 clay Substances 0.000 description 1
• 229960003009 clopidogrel Drugs 0.000 description 1
• GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
• 229960003920 cocaine Drugs 0.000 description 1
• 229940108538 colistimethate Drugs 0.000 description 1
• 108700028201 colistinmethanesulfonic acid Proteins 0.000 description 1
• 230000037319 collagen production Effects 0.000 description 1
• 238000002591 computed tomography Methods 0.000 description 1
• 239000000356 contaminant Substances 0.000 description 1
• 238000013270 controlled release Methods 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 238000012937 correction Methods 0.000 description 1
• 229940111134 coxibs Drugs 0.000 description 1
• 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 238000004925 denaturation Methods 0.000 description 1
• 230000036425 denaturation Effects 0.000 description 1
• 238000001739 density measurement Methods 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
• 238000002405 diagnostic procedure Methods 0.000 description 1
• 230000005292 diamagnetic effect Effects 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• 235000014113 dietary fatty acids Nutrition 0.000 description 1
• 230000010339 dilation Effects 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• 229910001873 dinitrogen Inorganic materials 0.000 description 1
• 230000001882 diuretic effect Effects 0.000 description 1
• 229940030606 diuretics Drugs 0.000 description 1
• PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
• 230000002222 downregulating effect Effects 0.000 description 1
• 229960004679 doxorubicin Drugs 0.000 description 1
• 239000003937 drug carrier Substances 0.000 description 1
• 238000012377 drug delivery Methods 0.000 description 1
• 231100000725 drug overdose Toxicity 0.000 description 1
• 238000013399 early diagnosis Methods 0.000 description 1
• 230000002497 edematous effect Effects 0.000 description 1
• 230000002526 effect on cardiovascular system Effects 0.000 description 1
• 238000001378 electrochemiluminescence detection Methods 0.000 description 1
• 208000028208 end stage renal disease Diseases 0.000 description 1
• 201000000523 end stage renal failure Diseases 0.000 description 1
• 230000003511 endothelial effect Effects 0.000 description 1
• 210000003989 endothelium vascular Anatomy 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
• 229960005542 ethidium bromide Drugs 0.000 description 1
• 125000004494 ethyl ester group Chemical group 0.000 description 1
• 230000001747 exhibiting effect Effects 0.000 description 1
• 238000000605 extraction Methods 0.000 description 1
• 210000001508 eye Anatomy 0.000 description 1
• 235000013861 fat-free Nutrition 0.000 description 1
• 229930195729 fatty acid Natural products 0.000 description 1
• 239000000194 fatty acid Substances 0.000 description 1
• 150000004665 fatty acids Chemical class 0.000 description 1
• 210000003608 fece Anatomy 0.000 description 1
• 210000003191 femoral vein Anatomy 0.000 description 1
• LZPBLUATTGKZBH-UHFFFAOYSA-L fenoprofen calcium Chemical compound O.O.[Ca+2].[O-]C(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1.[O-]C(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1 LZPBLUATTGKZBH-UHFFFAOYSA-L 0.000 description 1
• 239000007850 fluorescent dye Substances 0.000 description 1
• PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 1
• 150000002251 gadolinium compounds Chemical class 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• 238000001502 gel electrophoresis Methods 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 239000007903 gelatin capsule Substances 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 239000003193 general anesthetic agent Substances 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 210000005086 glomerual capillary Anatomy 0.000 description 1
• 229960003180 glutathione Drugs 0.000 description 1
• 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
• 150000002314 glycerols Chemical class 0.000 description 1
• 150000002334 glycols Chemical class 0.000 description 1
• 239000003102 growth factor Substances 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 230000000004 hemodynamic effect Effects 0.000 description 1
• 208000007386 hepatic encephalopathy Diseases 0.000 description 1
• 235000008216 herbs Nutrition 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 239000001257 hydrogen Substances 0.000 description 1
• 229910052739 hydrogen Inorganic materials 0.000 description 1
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
• WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
• 229960002591 hydroxyproline Drugs 0.000 description 1
• 230000001146 hypoxic effect Effects 0.000 description 1
• HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
• 229960001101 ifosfamide Drugs 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• 238000002991 immunohistochemical analysis Methods 0.000 description 1
• 238000011532 immunohistochemical staining Methods 0.000 description 1
• 229960003444 immunosuppressant agent Drugs 0.000 description 1
• 239000003018 immunosuppressive agent Substances 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 238000000338 in vitro Methods 0.000 description 1
• 238000001727 in vivo Methods 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• 229960001936 indinavir Drugs 0.000 description 1
• CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 210000004969 inflammatory cell Anatomy 0.000 description 1
• 230000002757 inflammatory effect Effects 0.000 description 1
• 230000004941 influx Effects 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 230000005764 inhibitory process Effects 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 230000002452 interceptive effect Effects 0.000 description 1
• 229940079322 interferon Drugs 0.000 description 1
• 210000002570 interstitial cell Anatomy 0.000 description 1
• 238000013152 interventional procedure Methods 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 239000000193 iodinated contrast media Substances 0.000 description 1
• PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
• 239000002611 ionic contrast media Substances 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• 229940029393 iophendylate Drugs 0.000 description 1
• 229940029379 iothalamate meglumine Drugs 0.000 description 1
• 229940029407 ioxaglate Drugs 0.000 description 1
• TYYBFXNZMFNZJT-UHFFFAOYSA-N ioxaglic acid Chemical compound CNC(=O)C1=C(I)C(N(C)C(C)=O)=C(I)C(C(=O)NCC(=O)NC=2C(=C(C(=O)NCCO)C(I)=C(C(O)=O)C=2I)I)=C1I TYYBFXNZMFNZJT-UHFFFAOYSA-N 0.000 description 1
• XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
• 230000002427 irreversible effect Effects 0.000 description 1
• 208000037906 ischaemic injury Diseases 0.000 description 1
• 239000007951 isotonicity adjuster Substances 0.000 description 1
• 239000004310 lactic acid Substances 0.000 description 1
• 235000014655 lactic acid Nutrition 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 201000010260 leiomyoma Diseases 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• 231100001231 less toxic Toxicity 0.000 description 1
• 231100000518 lethal Toxicity 0.000 description 1
• 230000001665 lethal effect Effects 0.000 description 1
• 230000003859 lipid peroxidation Effects 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• 208000007903 liver failure Diseases 0.000 description 1
• 231100000835 liver failure Toxicity 0.000 description 1
• 210000005228 liver tissue Anatomy 0.000 description 1
• 239000012160 loading buffer Substances 0.000 description 1
• 231100000053 low toxicity Toxicity 0.000 description 1
• 210000004072 lung Anatomy 0.000 description 1
• 230000004199 lung function Effects 0.000 description 1
• 210000004698 lymphocyte Anatomy 0.000 description 1
• 239000012139 lysis buffer Substances 0.000 description 1
• 238000010841 mRNA extraction Methods 0.000 description 1
• 229920002521 macromolecule Polymers 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 210000004962 mammalian cell Anatomy 0.000 description 1
• KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
• 229960004963 mesalazine Drugs 0.000 description 1
• 108020004999 messenger RNA Proteins 0.000 description 1
• 229930182817 methionine Chemical group 0.000 description 1
• LSDPWZHWYPCBBB-UHFFFAOYSA-O methylsulfide anion Chemical compound [SH2+]C LSDPWZHWYPCBBB-UHFFFAOYSA-O 0.000 description 1
• 230000004898 mitochondrial function Effects 0.000 description 1
• 229960004857 mitomycin Drugs 0.000 description 1
• 230000011278 mitosis Effects 0.000 description 1
• 108091005601 modified peptides Proteins 0.000 description 1
• 239000003846 monomeric ionic contrast media Substances 0.000 description 1
• BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical class O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 1
• 230000000877 morphologic effect Effects 0.000 description 1
• 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
• 238000009608 myelography Methods 0.000 description 1
• 208000010125 myocardial infarction Diseases 0.000 description 1
• 229940031182 nanoparticles iron oxide Drugs 0.000 description 1
• 230000037125 natural defense Effects 0.000 description 1
• 229940053050 neomycin sulfate Drugs 0.000 description 1
• 230000001537 neural effect Effects 0.000 description 1
• 238000006396 nitration reaction Methods 0.000 description 1
• 229920001220 nitrocellulos Polymers 0.000 description 1
• 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 238000007899 nucleic acid hybridization Methods 0.000 description 1
• 230000000414 obstructive effect Effects 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• 108010007425 oligomycin sensitivity conferring protein Proteins 0.000 description 1
• 238000002515 oligonucleotide synthesis Methods 0.000 description 1
• 229920001542 oligosaccharide Polymers 0.000 description 1
• 150000002482 oligosaccharides Chemical class 0.000 description 1
• 230000000771 oncological effect Effects 0.000 description 1
• 238000001543 one-way ANOVA Methods 0.000 description 1
• 230000008816 organ damage Effects 0.000 description 1
• 230000020477 pH reduction Effects 0.000 description 1
• 230000036407 pain Effects 0.000 description 1
• 210000000496 pancreas Anatomy 0.000 description 1
• FIKAKWIAUPDISJ-UHFFFAOYSA-L paraquat dichloride Chemical compound [Cl-].[Cl-].C1=C[N+](C)=CC=C1C1=CC=[N+](C)C=C1 FIKAKWIAUPDISJ-UHFFFAOYSA-L 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 230000007310 pathophysiology Effects 0.000 description 1
• 229960001639 penicillamine Drugs 0.000 description 1
• 150000002960 penicillins Chemical class 0.000 description 1
• XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 1
• 229960004448 pentamidine Drugs 0.000 description 1
• 230000010412 perfusion Effects 0.000 description 1
• 238000005502 peroxidation Methods 0.000 description 1
• 239000000575 pesticide Substances 0.000 description 1
• 230000008782 phagocytosis Effects 0.000 description 1
• DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
• 229960002695 phenobarbital Drugs 0.000 description 1
• WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
• BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
• 230000001766 physiological effect Effects 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 230000036470 plasma concentration Effects 0.000 description 1
• 229920001993 poloxamer 188 Polymers 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 229920000642 polymer Polymers 0.000 description 1
• 238000003752 polymerase chain reaction Methods 0.000 description 1
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
• 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
• 229920000136 polysorbate Polymers 0.000 description 1
• 229950008882 polysorbate Drugs 0.000 description 1
• 229920000053 polysorbate 80 Polymers 0.000 description 1
• 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
• 230000001323 posttranslational effect Effects 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 229910000160 potassium phosphate Inorganic materials 0.000 description 1
• 235000011009 potassium phosphates Nutrition 0.000 description 1
• 230000002206 pro-fibrotic effect Effects 0.000 description 1
• 239000000047 product Substances 0.000 description 1
• 230000005522 programmed cell death Effects 0.000 description 1
• 230000007425 progressive decline Effects 0.000 description 1
• 230000000770 proinflammatory effect Effects 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 235000019833 protease Nutrition 0.000 description 1
• 230000006318 protein oxidation Effects 0.000 description 1
• 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
• 230000004088 pulmonary circulation Effects 0.000 description 1
• 238000011002 quantification Methods 0.000 description 1
• 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
• 229960000948 quinine Drugs 0.000 description 1
• 239000002516 radical scavenger Substances 0.000 description 1
• 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
• 239000011541 reaction mixture Substances 0.000 description 1
• 230000009719 regenerative response Effects 0.000 description 1
• 230000001105 regulatory effect Effects 0.000 description 1
• 238000007634 remodeling Methods 0.000 description 1
• 210000002254 renal artery Anatomy 0.000 description 1
• 208000015670 renal artery disease Diseases 0.000 description 1
• 230000008439 repair process Effects 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 230000029058 respiratory gaseous exchange Effects 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 229960001225 rifampicin Drugs 0.000 description 1
• JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
• 230000003248 secreting effect Effects 0.000 description 1
• 230000028327 secretion Effects 0.000 description 1
• 208000026775 severe diarrhea Diseases 0.000 description 1
• 238000002603 single-photon emission computed tomography Methods 0.000 description 1
• 229960002930 sirolimus Drugs 0.000 description 1
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
• UCPVOMHRDXMAIZ-UHFFFAOYSA-M sodium acetrizoate Chemical compound [Na+].CC(=O)NC1=C(I)C=C(I)C(C([O-])=O)=C1I UCPVOMHRDXMAIZ-UHFFFAOYSA-M 0.000 description 1
• ZEYOIOAKZLALAP-UHFFFAOYSA-M sodium amidotrizoate Chemical compound [Na+].CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I ZEYOIOAKZLALAP-UHFFFAOYSA-M 0.000 description 1
• 125000004436 sodium atom Chemical group 0.000 description 1
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
• 239000001488 sodium phosphate Substances 0.000 description 1
• 229910000162 sodium phosphate Inorganic materials 0.000 description 1
• 159000000000 sodium salts Chemical class 0.000 description 1
• RMLUKZWYIKEASN-UHFFFAOYSA-M sodium;2-amino-9-(2-hydroxyethoxymethyl)purin-6-olate Chemical compound [Na+].O=C1[N-]C(N)=NC2=C1N=CN2COCCO RMLUKZWYIKEASN-UHFFFAOYSA-M 0.000 description 1
• 239000007787 solid Substances 0.000 description 1
• 239000002904 solvent Substances 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 235000000346 sugar Nutrition 0.000 description 1
• 150000005846 sugar alcohols Chemical class 0.000 description 1
• 229940124530 sulfonamide Drugs 0.000 description 1
• 150000003456 sulfonamides Chemical class 0.000 description 1
• 239000000725 suspension Substances 0.000 description 1
• 238000001308 synthesis method Methods 0.000 description 1
• 230000002194 synthesizing effect Effects 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 239000003826 tablet Substances 0.000 description 1
• 229960001967 tacrolimus Drugs 0.000 description 1
• QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 235000012222 talc Nutrition 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 201000005060 thrombophlebitis Diseases 0.000 description 1
• 229960005001 ticlopidine Drugs 0.000 description 1
• PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
• 229960000707 tobramycin Drugs 0.000 description 1
• NLVFBUXFDBBNBW-PBSUHMDJSA-S tobramycin(5+) Chemical compound [NH3+][C@@H]1C[C@H](O)[C@@H](C[NH3+])O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H]([NH3+])[C@H](O)[C@@H](CO)O2)O)[C@H]([NH3+])C[C@@H]1[NH3+] NLVFBUXFDBBNBW-PBSUHMDJSA-S 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
• 230000007723 transport mechanism Effects 0.000 description 1
• 229960001288 triamterene Drugs 0.000 description 1
• YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
• 230000001960 triggered effect Effects 0.000 description 1
• 230000007306 turnover Effects 0.000 description 1
• 210000001635 urinary tract Anatomy 0.000 description 1
• 238000007487 urography Methods 0.000 description 1
• MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 1
• 229960000604 valproic acid Drugs 0.000 description 1
• MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
• 229960003165 vancomycin Drugs 0.000 description 1
• MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
• 230000002792 vascular Effects 0.000 description 1
• 208000019553 vascular disease Diseases 0.000 description 1
• 210000005166 vasculature Anatomy 0.000 description 1
• 230000024883 vasodilation Effects 0.000 description 1
• 235000015112 vegetable and seed oil Nutrition 0.000 description 1
• 235000019871 vegetable fat Nutrition 0.000 description 1
• 201000001862 viral hepatitis Diseases 0.000 description 1
• 235000012431 wafers Nutrition 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 239000002699 waste material Substances 0.000 description 1
• 238000001262 western blot Methods 0.000 description 1
• 150000003738 xylenes Chemical class 0.000 description 1